[Morphine-induced late cardioprotection: potential role of inducible nitric oxide synthase]. 2004

En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
Department of Cardiac Surgery, First Affiliated Hospital, China Medical University, Shenyang 110001, China. shienyi2002@hotmail.com

OBJECTIVE To explore the late cardioprotection induced by morphine preconditioning and determine the role of inducible nitric oxide synthase (iNOS) in mediating this effect. METHODS Thirty-two wild type (WT) mice and 16 iNOS gene knockout mice, totally 48 mice, underwent ligation of the left anterior descending coronary artery (LAD) for 45 minutes and reperfusion for 120 minutes. The 32 wild type mice were randomly divided into 4 groups of 8 mice: WT control group, 24 hours before the heart occlusion, normal saline was given; WT + morphine group, 24 hours before the heart occlusion morphine was administered; WT + SMT group, 24 hours before the heart occlusion normal saline was administered and 30 minutes before heart occlusion S-methylthiourea sulfate (SMT), a selective inhibitor of iNOS, was administered; and WT + morphine + SMT group, 24 hours before the heart occlusion morphine was administered and 30 minutes before heart occlusion SMT was administered. The 16 iNOS gene knockout mice were randomly divided into 2 groups of 8 mice: iNOS (-/-) control group (24 hours before the heart occlusion normal saline was given) and iNOS (-/-) + morphine group (24 hours before heart occlusion. morphine was administered). One hundred and twenty minutes after reperfusion, the LAD was re-ligated at the original site for all the mice. Evans blue was injected via right carotid artery catheterization to stain the non-ischemic area of the heart. Then the hearts of all mice were taken out, cut into 5 pieces with similar thickness, and put into the solution of 2, 3, 5-triphenyltetrazolium chloride (TTC). The heart was fixed in formalin solution, underwent digital photography, and weighed. NIH Image software was used to calculate the area of the left ventricle (LV), infarct size (IS), and area at risk (AAR). The size of myocardial ischemia was expressed as AAR/LV, and the scope of myocardial infarction was expressed as IS/AAR. RESULTS The IS/AAR of the WT control group was 43% +/- 5%, significantly larger than that of the WT + morphine group (22% +/- 4% P < 0.05). The value of IS/AAR of the WT + morphine + SMI group was 43% +/- 4%, not significantly different from that of the WT control group (P > 0.05). The IS/AAR of the iNOS (-/-) control group was 44% +/- 4%, also not significantly different from that of the WT control group (P > 0.05). The IS/AAR of the iNOS (-/-) + morphine group was 42% +/- 5%, not significantly different from that of the iNOS (-/-) control group (P > 0.05). CONCLUSIONS Morphine preconditioning induces late cardioprotection in mice via an iNOS-dependent pathway. Pretreatment with SMT abolishes the morphine-induced reduction of infarct size. In addition, morphine fails to reduce infarct size in iNOS gene knockout mice.

UI MeSH Term Description Entries
D008297 Male Males
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015428 Myocardial Reperfusion Injury Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm. Reperfusion Injury, Myocardial,Injury, Myocardial Reperfusion,Myocardial Ischemic Reperfusion Injury,Injuries, Myocardial Reperfusion,Myocardial Reperfusion Injuries,Reperfusion Injuries, Myocardial
D015971 Gene Expression Regulation, Enzymologic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in enzyme synthesis. Enzymologic Gene Expression Regulation,Regulation of Gene Expression, Enzymologic,Regulation, Gene Expression, Enzymologic
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
December 1999, European journal of medical research,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
October 2006, Cardiovascular research,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
May 2002, Nitric oxide : biology and chemistry,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
September 2006, Life sciences,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
December 2015, Clinical and molecular hepatology,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
August 2001, Inflammation,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
July 2004, Journal of toxicology and environmental health. Part A,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
December 1998, American journal of respiratory and critical care medicine,
En-Yi Shi, and Xiao-Jing Jiang, and Han Bai, and Yoshiki Nakajima
April 2000, Alimentary pharmacology & therapeutics,
Copied contents to your clipboard!